Should atrial fibrillation be considered a vascular disease? The need for a comprehensive vascular approach

References

• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American heart Association. Circulation. 2023;147(8):e93–e621. doi: 10.1161/CIR.0000000000001123
   PubMed Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. doi: 10.1177/1747493019897870
   PubMed Web of Science ®Google Scholar
• Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st Century: novel methods and new insights. Circ Res. 2020;127(1):4–20. doi:10.1161/CIRCRESAHA.120.316340
   PubMed Web of Science ®Google Scholar
• Theunissen LJHJ, van de Pol JAA, van Steenbergen GJ, et al. The prognostic value of quality of life in atrial fibrillation on patient value. Health Qual Life Outcomes. 2023;21(1):33. doi: 10.1186/s12955-023-02112-2
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313–320. doi:10.1161/CIRCOUTCOMES.110.958165
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Kim S, Fonarow GC, et al. Drivers of hospitalization for patients with atrial fibrillation: results from the outcomes registry for better Informed treatment of atrial fibrillation (ORBIT-AF). Am Heart J. 2014;167(5):735–742. doi: 10.1016/j.ahj.2014.02.003
   PubMed Web of Science ®Google Scholar
• Gullón A, Formiga F, Díez-Manglano J, et al. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation. Intern Emerg Med. 2019;14(1):59–69. doi: 10.1007/s11739-018-1938-3
   PubMed Web of Science ®Google Scholar
• An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: the Fushimi atrial fibrillation registry. Eur Heart J Qual Care Clin Outcomes. 2019;5(1):35–42. doi: 10.1093/ehjqcco/qcy033
   PubMed Web of Science ®Google Scholar
• DeVore AD, Hellkamp AS, Becker RC, et al. Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace. 2016;18(8):1135–1142. doi: 10.1093/europace/euv404
   PubMed Web of Science ®Google Scholar
• Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128(20):2192–2201. doi: 10.1161/CIRCULATIONAHA.112.000491
   PubMed Web of Science ®Google Scholar
• Senoo K, Lip GY, Lane DA, et al. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS trial. Stroke. 2015;46(9):2523–2528. doi: 10.1161/STROKEAHA.115.009487
   PubMed Web of Science ®Google Scholar
• Alonso A, Almuwaqqat Z, Chamberlain A. Mortality in atrial fibrillation. Is it changing? trends. Cardiovasc Med. 2021;31(8):469–473. doi:10.1016/j.tcm.2020.10.010
   Google Scholar
• Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627–628. doi:10.1038/nrcardio.2017.153
   PubMed Web of Science ®Google Scholar
• Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the ‘atrial fibrillation better care’ (ABC) pathway in patients with atrial fibrillation. Thromb Haemost. 2022;122(3):406–414. doi: 10.1055/a-1515-9630
   PubMedGoogle Scholar
• Olesen JB, Gislason GH, Torp-Pedersen C, et al. Atrial fibrillation and vascular disease–a bad combination. Clin Cardiol. 2012;35(Suppl 1):15–20. doi:10.1002/clc.20955
   PubMedGoogle Scholar
• Zhou X, SC D Jr. Evidence for inflammation as a driver of atrial fibrillation. Front Cardiovasc Med. 2020;29(7):62. doi:10.3389/fcvm.2020.00062
   Google Scholar
• Youn JY, Zhang J, Zhang Y, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol. 2013;62:72–79. doi: 10.1016/j.yjmcc.2013.04.019
   PubMed Web of Science ®Google Scholar
• Bunch TJ, May HT. Atrial fibrillation: a risk factor or risk marker? Eur Heart J. 2016;37(38):2890–2892. doi:10.1093/eurheartj/ehw313
   PubMed Web of Science ®Google Scholar
• Malik V, Ganesan AN, Selvanayagam JB, et al. Is atrial fibrillation a stroke risk factor or risk marker? An appraisal using the Bradford Hill framework for causality. Heart Lung Circ. 2020;29(1):86–93. doi:10.1016/j.hlc.2019.08.005
   PubMed Web of Science ®Google Scholar
• Corban MT, Toya T, Ahmad A, et al. Atrial fibrillation and endothelial dysfunction: a potential link? Mayo. Clin Proc. 2021;96(6):1609–1621. doi:10.1016/j.mayocp.2020.11.005
   Google Scholar
• Barrios V, Almendro-Delia M, Facila L, et al. Rivaroxaban: searching the integral vascular protection. Expert Rev Clin Pharmacol. 2018;11(7):719–728. doi: 10.1080/17512433.2018.1495559
   PubMed Web of Science ®Google Scholar
• Posthuma JJ, Posma JJN, van Oerle R, et al. Targeting coagulation factor Xa promotes regression of advanced atherosclerosis in apolipoprotein-E deficient mice. Sci Rep. 2019;9(1):3909. doi: 10.1038/s41598-019-40602-w
   PubMedGoogle Scholar
• Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242(2):639–646. doi: 10.1016/j.atherosclerosis.2015.03.023
   PubMed Web of Science ®Google Scholar
• Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015;14(1):81. doi: 10.1186/s12933-015-0243-y
   PubMedGoogle Scholar
• Namba S, Yamaoka-Tojo M, Kakizaki R, et al. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017;32(8):977–982. doi: 10.1007/s00380-017-0950-2
   PubMed Web of Science ®Google Scholar
• Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, et al. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol. 2018;84(2):280–291. doi: 10.1111/bcp.13440
   PubMed Web of Science ®Google Scholar
• Liu J, Nishida M, Inui H, et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction. J Atheroscler Thromb. 2019;26(10):915–930. doi: 10.5551/jat.48405
   PubMed Web of Science ®Google Scholar
• Petzold T, Thienel M, Dannenberg L, et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res. 2020;126(4):486–500. doi: 10.1161/CIRCRESAHA.119.315099
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang Z, Chen W, et al. Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways. PeerJ. 2023;11:e16097. doi:10.7717/peerj.16097
   PubMed Web of Science ®Google Scholar
• Garcia-Fernandez A, Roldan V, Rivera-Caravaca JM, et al. Applicability of the modified CHA2DS2-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. Eur J Intern Med. 2017;38:e21–e22. doi:10.1016/j.ejim.2016.11.006
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi:10.7326/0003-4819-146-12-200706190-00007
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP. Braunwald E et al comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676. doi: 10.1093/europace/euab065
   PubMed Web of Science ®Google Scholar
• Macha K, Marsch A, Siedler G, et al. Cerebral ischemia in patients on direct oral anticoagulants. Stroke. 2019;50(4):873–879. doi: 10.1161/STROKEAHA.118.023877
   PubMed Web of Science ®Google Scholar
• Hellwig S, Grittner U, Audebert H, et al. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. EP Europace. 2018;20(4):569–574. doi:10.1093/europace/eux087
   PubMed Web of Science ®Google Scholar
• Meinel TR, Frey S, Arnold M, et al. Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants—a systematic review. PLoS One. 2019;14(3):e0213379. doi: 10.1371/journal.pone.0213379
   PubMed Web of Science ®Google Scholar
• Savelieva I, Fumagalli S, Kenny RA, et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2023;25(4):1249–1276. doi: 10.1093/europace/euac123
   PubMed Web of Science ®Google Scholar
• Pilotto A, Veronese N, Polidori MC, et al. The role of prognostic stratification on prescription of anticoagulants in older patients with atrial fibrillation: a multicenter, observational, prospective European study (EUROSAF). Ann Med. 2022;54(1):2411–2419. doi: 10.1080/07853890.2022.2117407
   PubMed Web of Science ®Google Scholar
• Caldeira D, Nunes-Ferreira A, Rodrigues R, et al. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr. 2019;81:209–214. doi:10.1016/j.archger.2018.12.013
   PubMed Web of Science ®Google Scholar
• Kogelschatz B, Zenger B, Steinberg BA, et al. Atrial fibrillation and the risk of early-onset dementia and cognitive decline: an updated review. Trends Cardiovasc Med. 2023. doi:10.1016/j.tcm.2023.01.005. Epub ahead of print.
   PubMedGoogle Scholar
• Bunch TJ. Atrial fibrillation and dementia. Circulation. 2020;142(7):618–620. doi:10.1161/CIRCULATIONAHA.120.045866
   PubMed Web of Science ®Google Scholar
• Wallace ER, Siscovick DS, Sitlani CM, et al. Incident atrial fibrillation and disability-free survival in the cardiovascular health study. J Am Geriatr Soc. 2016;64(4):838–843. doi: 10.1111/jgs.14037
   PubMed Web of Science ®Google Scholar
• Papanastasiou CA, Theochari CA, Zareifopoulos N, et al. Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(10):3122–3135. doi: 10.1007/s11606-021-06954-8
   PubMed Web of Science ®Google Scholar
• Kalloo AE, Slouha E, Gallagher CP, et al. Anticoagulants and dementia: a systematic review. Cureus. 2023;15(5):e39693. doi:10.7759/cureus.39693
   PubMed Web of Science ®Google Scholar
• Callizo J, Feltgen N, Ammermann A, et al. Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy. PLoS One. 2017;12(8):e0181766. doi: 10.1371/journal.pone.0181766
   PubMed Web of Science ®Google Scholar
• Zenger B, Rizzi S, Steinberg BA, et al. This is Your brain, and this is Your brain on atrial fibrillation: the roles of cardiac malperfusion events and vascular dysfunction in cognitive impairment. Arrhythm Electrophysiol Rev. 2023;12:e01. doi:10.15420/aer.2022.29
   PubMed Web of Science ®Google Scholar
• Zeitler EP, Bunch TJ, Khanna R, et al. Comparative risk of dementia among patients with atrial fibrillation treated with catheter ablation versus anti-arrhythmic drugs. Am Heart J. 2022;254:194–202. doi:10.1016/j.ahj.2022.09.007
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114. doi: 10.1001/jamainternmed.2013.11912
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Lopez F, O’Neal WT, et al. Atrial fibrillation and risk of ST-Segment-elevation versus non-ST-Segment-elevation myocardial infarction: the atherosclerosis risk in communities (ARIC) study. Circulation. 2015;131(21):1843–1850. doi: 10.1161/CIRCULATIONAHA.114.014145
   PubMed Web of Science ®Google Scholar
• O’Neal WT, Sangal K, Zhang ZM, et al. Atrial fibrillation and incident myocardial infarction in the elderly. Clin Cardiol. 2014;37(12):750–755. doi:10.1002/clc.22339
   PubMed Web of Science ®Google Scholar
• Pastori D, Pignatelli P, Angelico F, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest. 2015;147(6):1644–1650. doi: 10.1378/chest.14-2414
   PubMed Web of Science ®Google Scholar
• Abolbashari M. Atherosclerosis and atrial fibrillation: double trouble. Curr Cardiol Rep. 2022;24(2):67–73. doi:10.1007/s11886-021-01625-w
   PubMed Web of Science ®Google Scholar
• Sanmartín Fernández M, Anguita Sánchez M, Arribas F, et al. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: the EMIR study. Cardiol J. 2022;29(4):601–609. doi: 10.5603/CJ.a2022.0044
   PubMed Web of Science ®Google Scholar
• Virani SS, Newby LK, Arnold SV, et al. AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2023 2023 Jul 14; Epub ahead of print. doi: 10.1016/j.jacc.2023.04.003
   Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• da Silva RM. Influence of inflammation and atherosclerosis in atrial fibrillation. Curr Atheroscler Rep. 2017;19(1). 2. doi: 10.1007/s11883-017-0639-0
   PubMed Web of Science ®Google Scholar
• Kristensen KE, Knage CC, Nyhegn LH, et al. Subclinical atherosclerosis is associated with incident atrial fibrillation: a systematic review and meta-analysis. EP Europace. 2020;22(7):991–1000. doi: 10.1093/europace/euaa030
   PubMed Web of Science ®Google Scholar
• Oancea AF, Jigoranu RA, Morariu PC, et al. Atrial fibrillation and chronic coronary ischemia: a challenging vicious circle. Life. 2023;13(6):1370. doi: 10.3390/life13061370
   PubMedGoogle Scholar
• Batta A, Hatwal J, Batta A, et al. Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship. World J Cardiol. 2023;15(5):229–243. doi:10.4330/wjc.v15.i5.229
   PubMed Web of Science ®Google Scholar
• Krishnan A, Sharma H, Yuan D, et al. The role of epicardial adipose tissue in the development of atrial fibrillation, coronary artery disease and chronic heart failure in the context of obesity and type 2 diabetes mellitus: a narrative review. J Cardiovasc Dev Dis. 2022;9(7):217. doi: 10.3390/jcdd9070217
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Berchuck SI, Chiswell K, et al. Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. Heart Rhythm. 2022;19(8):1237–1244. doi: 10.1016/j.hrthm.2021.12.020
   PubMed Web of Science ®Google Scholar
• Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of hypertension endorsed by the European renal Association (ERA) and the international Society of hypertension (ISH). J Hypertens Jun. 2023;21. Epub ahead of print. doi: 10.1097/HJH.0000000000003480
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the international lipid Expert panel (ILEP). Prog Cardiovasc Dis Mar Epub ahead of print. 2023;7:2–11. doi: 10.1016/j.pcad.2023.03.001
   Google Scholar
• Gupta V, Munjal JS, Jhajj P, et al. Obesity and atrial fibrillation: a narrative review. Cureus. 2022;14(11):e31205. doi:10.7759/cureus.31205
   PubMed Web of Science ®Google Scholar
• Choi S, Chang J, Kim K, et al. Association of smoking cessation after atrial fibrillation diagnosis on the risk of cardiovascular disease: a cohort study of South Korean men. BMC Public Health. 2020;20(1):168. doi: 10.1186/s12889-020-8275-y
   PubMed Web of Science ®Google Scholar
• Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–1407. doi: 10.1056/NEJMoa1915922
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–1316. doi: 10.1056/NEJMoa2019422
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
   PubMed Web of Science ®Google Scholar
• Steensig K, Olesen KKW, Thim T, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost. 2018;118(12):2162–2170. doi: 10.1055/s-0038-1675401
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–1113. doi: 10.1056/NEJMoa1904143
   PubMed Web of Science ®Google Scholar
• Brunetti ND, Tricarico L, De Gennaro L, et al. Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: dual or triple approach? Int J Cardiol Heart Vasc. 2020;29:100569. doi: 10.1016/j.ijcha.2020.100569
   PubMed Web of Science ®Google Scholar
• Kupó P, Szakács Z, Solymár M, et al. Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis. Angiology. 2020;71(1):27–37. doi: 10.1177/0003319719874255
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D. Therapeutic uncertainties: first finding of atrial fibrillation in acute coronary syndrome. Eur Heart J Suppl. 2022;24(Suppl I):I43–I46. doi:10.1093/eurheartjsupp/suac072
   PubMedGoogle Scholar
• Petersen JK, Butt JH, Yafasova A, et al. Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first- time detected atrial fibrillation: a nationwide study. Eur Heart J. 2021;42(44):4553–4561. doi: 10.1093/eurheartj/ehab575
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. Aug 25 Epub ahead of print. doi: 10.1093/eurheartj/ehad191
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6A):2D–8D. doi:10.1016/S0002-9149(02)03373-8
   PubMed Web of Science ®Google Scholar
• Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–427. doi: 10.1056/NEJMoa1707855
   PubMed Web of Science ®Google Scholar
• Jin H, Zhu K, Wang L, et al. Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: a network meta-analysis. Thromb Res. 2020;196:109–119. doi:10.1016/j.thromres.2020.08.021
   PubMed Web of Science ®Google Scholar
• Vitalis A, Shantsila A, Proietti M, et al. Peripheral arterial disease in patients with atrial fibrillation: the AFFIRM study. Am J Med. 2021;134(4):514–518. doi: 10.1016/j.amjmed.2020.08.026
   PubMed Web of Science ®Google Scholar
• Anandasundaram B, Lane DA, Apostolakis S, et al. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost. 2013;11(5):975–987. doi:10.1111/jth.12177
   PubMed Web of Science ®Google Scholar
• Zhu J, Tan X, Zhou JZ. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2021;44(8):1050–1057. doi: 10.1002/clc.23678
   PubMed Web of Science ®Google Scholar
• Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003;89(6):1058–1063. doi: 10.1055/s-0037-1613408
   PubMed Web of Science ®Google Scholar
• Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495–502. doi:10.1253/circj.CJ-15-0138
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1
   PubMed Web of Science ®Google Scholar
• Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J Cardiovasc Dis Res. 2010;1(1):10–11. doi:10.4103/0975-3583.59978
   PubMedGoogle Scholar
• Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: a nationwide report. Diab Vasc Dis Res. 2018;15(1):31–38. doi:10.1177/1479164117735013
   PubMed Web of Science ®Google Scholar
• Xu J, Sun Y, Gong D, et al. Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: a meta-analysis. Front Endocrinol. 2022;13:921159. doi: 10.3389/fendo.2022.921159
   PubMed Web of Science ®Google Scholar
• Aune D, Feng T, Schlesinger S, et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501–511. doi:10.1016/j.jdiacomp.2018.02.004
   PubMed Web of Science ®Google Scholar
• Tadic M, Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: from mechanisms to clinical practice. Arch Cardiovasc Dis. 2015;108(4):269–276. doi:10.1016/j.acvd.2015.01.009
   PubMed Web of Science ®Google Scholar
• Leopoulou M, Theofilis P, Kordalis A, et al. Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment. World J Diabetes. 2023;14(5):512–527. doi: 10.4239/wjd.v14.i5.512
   PubMed Web of Science ®Google Scholar
• Nelson WW, Choi JC, Vanderpoel J, et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2013;112(4):509–512. doi: 10.1016/j.amjcard.2013.04.013
   PubMed Web of Science ®Google Scholar
• Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med. 2018;35(5):548–556. doi:10.1111/dme.13600
   PubMed Web of Science ®Google Scholar
• Alwafi H, Alotaibi B, Naser AY, et al. The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: a systematic review. Saudi Pharm J. 2021;29(12):1374–1382. doi: 10.1016/j.jsps.2021.11.001
   PubMed Web of Science ®Google Scholar
• Gao J, Xue G, Zhan G, et al. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. 2022;9:1011429. doi:10.3389/fcvm.2022.1011429
   PubMed Web of Science ®Google Scholar
• Zheng RJ, Wang Y, Tang JN, et al. Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(2):e145–e152. doi: 10.1097/FJC.0000000000001183
   PubMed Web of Science ®Google Scholar
• Wei J, Wang R, Ye H, et al. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol. 2022;13:910256. doi:10.3389/fendo.2022.910256
   PubMed Web of Science ®Google Scholar
• Hart RG, Eikelboom JW, Brimble KS, et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29(7 Suppl):S71–78. doi:10.1016/j.cjca.2013.04.005
   PubMed Web of Science ®Google Scholar
• Banerjee A, Fauchier L, Vourc’h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley atrial fibrillation project. Chest. 2014;145(6):1370–1382. doi:10.1378/chest.13-2103
   PubMed Web of Science ®Google Scholar
• Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi:10.1136/bmj.i4482
   PubMed Web of Science ®Google Scholar
• Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013;168(5):4678–4684. doi: 10.1016/j.ijcard.2013.07.179
   PubMed Web of Science ®Google Scholar
• Airy M, Schold JD, Jolly SE, et al. Cause-specific mortality in patients with chronic kidney disease and atrial fibrillation. Am J Nephrol. 2018;48(1):36–45. doi: 10.1159/000491023
   PubMed Web of Science ®Google Scholar
• Voroneanu L, Ortiz A, Nistor I, et al. Atrial fibrillation in chronic kidney disease. Eur J Intern Med. 2016;33:3–13. doi:10.1016/j.ejim.2016.04.007
   PubMed Web of Science ®Google Scholar
• Gadde S, Kalluru R, Cherukuri SP, et al. Atrial fibrillation in chronic kidney disease: an overview. Cureus. 2022;14(8):e27753. doi:10.7759/cureus.27753
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang Y, He F. Insights into concomitant atrial fibrillation and chronic kidney disease. Rev Cardiovasc Med. 2022;23(3):105. doi:10.31083/j.rcm2303105
   PubMed Web of Science ®Google Scholar
• Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117(4):1046–1059. doi:10.1093/cvr/cvaa258
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts. Circulation. 2013;127(2):224–232. doi: 10.1161/CIRCULATIONAHA.112.107128
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Kamper A, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–635. doi: 10.1056/NEJMoa1105594
   PubMed Web of Science ®Google Scholar
• Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018;14(5):337–351. doi:10.1038/nrneph.2018.19
   PubMed Web of Science ®Google Scholar
• Barrios V, Górriz JL. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. J Comp Eff Res. 2015;4(6):651–664. doi:10.2217/cer.15.44
   PubMed Web of Science ®Google Scholar
• López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, et al. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022;52(9):e13788. doi: 10.1111/eci.13788
   PubMed Web of Science ®Google Scholar
• Shahid F, Pastori D, Violi F, et al. Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation. Pharmacol Res. 2018;132:149–159. doi:10.1016/j.phrs.2018.04.019
   PubMed Web of Science ®Google Scholar
• Jover E, Marín F, Roldán V, et al. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Ann Med. 2013;45(3):274–290. doi:10.3109/07853890.2012.732702
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Kaikita K, Ito M, et al. Improvement of vascular endothelial function reflects nonrecurrence after catheter ablation for atrial fibrillation. J Am Heart Assoc. 2021;10(17):e021551. doi: 10.1161/JAHA.121.021551
   PubMed Web of Science ®Google Scholar
• Rivinius R, Helmschrott M, Ruhparwar A, et al. Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality. ESC Heart Fail. 2020;7(1):176–187. doi: 10.1002/ehf2.12549
   PubMed Web of Science ®Google Scholar
• Fumagalli S, Gabbai D, Nreu B, et al. Age, left atrial dimension and arterial stiffness after external cardioversion of atrial fibrillation. A vascular component in arrhythmia maintenance? Results from a preliminary study. Aging Clin Exp Res. 2014;26(3):327–330. doi: 10.1007/s40520-013-0173-z
   PubMed Web of Science ®Google Scholar
• Nielsen AB, Skaarup KG, Djernæs K, et al. Association between pulmonary vascular volume and cardiac structure and function in patients with atrial fibrillation. Am J Cardiol. 2023;205:182–189. doi: 10.1016/j.amjcard.2023.07.119
   PubMed Web of Science ®Google Scholar
• Castro Conde A, Marzal Martín D, Campuzano Ruiz R, et al. Comprehensive cardiovascular and renal protection in patients with type 2 diabetes. J Clin Med. 2023;12(12):3925. doi: 10.3390/jcm12123925
   PubMed Web of Science ®Google Scholar
• Dai C, Kong B, Shuai W, et al. Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease. ESC Heart Fail. 2023;10(1):578–593. doi: 10.1002/ehf2.14169
   PubMed Web of Science ®Google Scholar
• Jang GW, Lee JM, Choi SW, et al. Vascular protective effects of new oral anticoagulants in patients with atrial fibrillation. J Clin Med. 2021;10(19):4332. doi: 10.3390/jcm10194332
   PubMed Web of Science ®Google Scholar
• Gawałko M, Lodziński P, Budnik M, et al. Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General long-term registry. Int J Clin Pract. 2021;75(3):e13701. doi: 10.1111/ijcp.13701
   PubMed Web of Science ®Google Scholar
• Coleman CI, Costa OS, Brescia CW, et al. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovasc Diabetol. 2021;20(1):52. doi:10.1186/s12933-021-01250-5
   PubMed Web of Science ®Google Scholar